Jeffrey R. Harris

Jeffrey R. Harris, PhD, currently serves as the Director and Translational Medicine Lead for ADC Development at Genmab since October 2018, overseeing the translational research strategies for Tivdak and other antibody-drug conjugates. Previously held positions include Director of the Translational Quantitative Sciences Department and Associate Director for Translational Research for Tisotumab Vedotin. Earlier experience includes roles as Principal Scientist and Senior Scientist in translational research at The Janssen Pharmaceutical Companies of Johnson & Johnson, focusing on CAR-T and biologic therapies for various cancers. Contributions to Celgene as a Senior Scientist involved preclinical and translational development of NK cell therapies. Founder of Triangle Biotech and extensive postdoctoral work at Duke University Medical Center underscores a strong background in hematopoietic research. Educational credentials include a PhD in Molecular Cell Biology and an MBA from the University of Florida, complemented by a BS in Biology from Virginia Tech.